R-biolin, the company’s lead biologic drug, aims to disrupt the $90 billion insulin market through a biosimilar manufacturing technique that can be ‘massively’ scaled to yield cost savings.
Moving forward, rBIO says it is now seeking strategic collaborations to propel R-biolin through the next phase of clinical development and bring the insulin therapy to diabetic patients worldwide.
“There has been a lot of talk in the media about reducing the cost of insulin for diabetic patients, but what is often overlooked is that the domestic demand for insulin will soon outpace the supply, leading to a new host of issues,” said rBIO CEO and co-founder Cameron Owen.
“We’re dedicated to addressing the growing demand for accessible insulin therapies, and today we’re thrilled to announce the viability of our highly scalable manufacturing process.”
Approximately 12% of the population in the United States has diabetes, which translates to roughly 40 million people.
With domestic demand for insulin continuing to increase, rBIO is hoping is to reduce the cost of insulin by 30%.
The drug was developed by a small team of scientists and has gone through extensive analytical characterizations by rBIO’s science team to ensure the comparability of R-biolin to currently available insulin products.
With the efficacy and quality now validated, rBIO is readying R-biolin for an imminent clinical trial.